UPC Opt-out Strategy for US Companies

The Unified Patent Court (UPC) has changed the enforcement landscape for European patents. Since June 2023, European patents granted by the EPO and their pending applications fall under the UPC's jurisdiction unless they are formally opted out. For US companies with European portfolios, the opt-out decision is one of the most consequential strategic moves of the post-grant phase — and it is not automatic.

The opt-out removes a patent or application from the UPC's competence and keeps enforcement and revocation actions in national courts. Until 1 June 2030, the opt-out is free and can be registered for any European patent, patent application or supplementary protection certificate that falls within the UPC's scope. After that date, the transitional regime will end and the opt-out opportunity will narrow. The window is long, but waiting is only sensible if you have a strategy.

The first question is whether the patent is worth litigating centrally. If the patent covers a core product in Germany, France, the Netherlands and Italy, the UPC's single decision across all participating states is a powerful plaintiff tool. A single injunction, damages award or seizure order can cover the largest EU markets at once. If your business model depends on cross-border enforcement, leaving the patent in the UPC system may be the right call.

The second question is whether you can tolerate central revocation. The same mechanism that makes the UPC attractive for plaintiffs also makes it dangerous for defendants. A single UPC revocation action can invalidate the patent across all participating states at once. For patents that are likely to be challenged — competitors in crowded fields, standard-essential patents, or patents in litigation-prone industries — the opt-out preserves the defensive value of forcing opponents to challenge the patent country by country.

Cost-benefit analysis should look at both sides of the docket. UPC proceedings are often cheaper than running parallel national actions, but they are not cheap. First-instance litigation at the UPC typically starts in the low six figures for a modest case. National proceedings can be more expensive in aggregate, but they are sequential and can be stopped or settled after the first country. For a portfolio of secondary patents, the opt-out spreads risk and avoids putting all value on one procedural table.

Timing matters. The opt-out must be registered before any UPC action starts in relation to the patent. Once a UPC action has begun, the patent is locked into the UPC system for the duration of those proceedings. If you wait until a competitor is already suing or threatening to sue, you may lose the option entirely. The safe approach is to make the opt-out decision as part of the post-grant review, not as a reactive emergency measure.

The unitary effect decision and the opt-out decision are related but separate. A Unitary Patent is always under UPC jurisdiction and cannot be opted out. A traditional European patent validated in participating states can be opted out. Many US companies choose a hybrid portfolio: Unitary Patents for broad EU coverage where central enforcement is desirable, and opted-out traditional patents for specific countries or technologies where central revocation risk is too high. The comparison between the two routes is covered in the [European Patent vs Unitary Patent guide](/blog/european-patent-vs-unitary-patent).

Implementation is straightforward but requires precision. The opt-out is registered through the UPC CMS by the patent proprietor or their representative. For patents with multiple proprietors, all proprietors must agree. For patents licensed exclusively, the licensee may need to be involved. The registration is effective from the date of entry in the register, and the patent is then excluded from the UPC's jurisdiction. The opt-out can be withdrawn later, returning the patent to UPC jurisdiction, but only if no national action has started in the meantime.

Common mistakes include opting out by default on every patent, leaving patents in the UPC without reviewing infringement exposure, and forgetting to update the decision as the portfolio evolves. Another error is treating the opt-out as a one-time exercise. New grants, new applications, acquisitions and licence deals should all trigger a fresh review of UPC jurisdiction.

For US companies, the practical workflow is usually this: at grant, decide whether to request unitary effect or validate traditionally; for every traditional European patent, decide whether to opt out based on enforcement plans, litigation risk, technology importance and competitor behaviour; register the opt-out before any UPC action arises; and review the portfolio quarterly as new grants and business priorities change. This is the same discipline that applies to validation and renewal decisions, which are covered in the [validating a European patent guide](/blog/validating-a-european-patent).

The role of a UPC representative is critical. Only European Patent Attorneys registered as UPC representatives and certain qualified lawyers can represent parties before the UPC. If you are considering UPC enforcement or defending a UPC revocation action, you need someone with direct UPC experience, not just EPO prosecution background. UPC procedure, local rules and the interplay between the UPC and national courts are still developing, and experience in the new court matters.

The key takeaway is that the UPC opt-out is a risk management tool, not a default setting. For some patents, the UPC's central enforcement is a strategic advantage. For others, the opt-out is the only way to avoid a single point of failure. The right answer depends on where you sell, where you might sue, where you might be sued, and how important the patent is to your portfolio. Make the decision at grant, document the reasoning, and review it as the business evolves. For a broader view of European patent strategy, see the [European Patents service page](/european-patents), and for UPC and EPO representation, visit Bauer IP.